【信达生物(01801.HK):全球首个GCG/GLP-1双受体激动减重药物信尔美® (玛仕度肽注射液)获批首个长期体重

智通财经
27 Jun
【信达生物(01801.HK):全球首个GCG/GLP-1双受体激动减重药物信尔美® (玛仕度肽注射液)获批首个长期体重控制适应症】智通财经APP讯,信达生物(01801.HK)发布公告,胰高血糖素(GCG)/胰高血糖素样肽-1 (GLP-1)双受体激动剂信尔美®(玛仕度肽注射液)的新药上市申请(NDA)获中国国家药品监督管理局(NMPA)批准上市,用于成人肥胖或超重患者的长期体重控制。信尔美®是全球首个GCG/GLP-1双受体激动减重药物,其独特的作用机制既能够增加减重效果,又能够直接降低内脏脂肪含量,带来全面的代谢获益,获评为2025年全球十大最受期待药物之一(FIERCE Pharma 2025)。

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10